AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine

[at noodls] – AstraZeneca and BIND Therapeutics announced today that they have entered into a strategic collaboration to develop and commercialise an Accurinâ„¢, a targeted and programmable cancer nanomedicine from BIND’s … more

View todays social media effects on AZN

View the latest stocks trending across Twitter. Click to view dashboard

See who Astrazeneca is hiring next, click here to view